The pathogenic oral–gut–liver axis: new understandings and clinical implications

References

• Consortium HMP. Structure, function and diversity of the healthy human microbiome. Nature. 2012 Jun;486(7402):207–214.
   PubMed Web of Science ®Google Scholar
• Consortium HMP. A framework for human microbiome research. Nature. 2012 Jun;486(7402):215–221.
   PubMed Web of Science ®Google Scholar
• Peterson J, Garges S, Giovanni M, et al. The NIH human microbiome project. Genome Res. 2009 Dec;19(12):2317–2323. .
   PubMed Web of Science ®Google Scholar
• Hillman ET, Lu H, Yao T, et al. Microbial ecology along the gastrointestinal tract. Microbes Environ. 2017 Dec;32(4):300–313. .
   PubMed Web of Science ®Google Scholar
• Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet. 2010 Jan;11(1):31–46.
   PubMed Web of Science ®Google Scholar
• Nagao-Kitamoto H, Shreiner AB, Gillilland MG, et al. Functional characterization of inflammatory bowel disease-associated gut dysbiosis in gnotobiotic mice. Cell Mol Gastroenterol Hepatol. 2016 Jul;2(4):468–481. .
   PubMed Web of Science ®Google Scholar
• Lynge Pedersen AM, Belstrøm D. The role of natural salivary defences in maintaining a healthy oral microbiota. J Dent. 2019;80(Suppl 1):S3–S12.
   PubMedGoogle Scholar
• Bodet C, Chandad F, Grenier D. Pathogenic potential of porphyromonas gingivalis, treponema denticola and tannerella forsythia, the red bacterial complex associated with periodontitis. Pathol Biol. 2007 Apr-May;55(3–4):154–162.
   PubMedGoogle Scholar
• Pérez-Chaparro PJ, Gonçalves C, Figueiredo LC, et al. Newly identified pathogens associated with periodontitis: a systematic review. J Dent Res. 2014 Sep;93(9):846–858. .
   PubMed Web of Science ®Google Scholar
• Graves DT, Corrêa JD, Silva TA. The oral microbiota is modified by systemic diseases. J Dent Res. 2019;98(2):148–156.
   PubMed Web of Science ®Google Scholar
• Minty M, Canceil T, Serino M, et al. Oral microbiota-induced periodontitis: a new risk factor of metabolic diseases. Rev Endocr Metab Disord. 2019;20(4):449–459. .
   PubMed Web of Science ®Google Scholar
• Kitamoto S, Nagao-Kitamoto H, Hein R, et al. The bacterial connection between the oral cavity and the gut diseases. J Dent Res. 2020 Aug;99(9):1021–1029. .
   PubMed Web of Science ®Google Scholar
• Acharya C, Sahingur SE, Bajaj JS. Microbiota, cirrhosis, and the emerging oral-gut-liver axis. JCI Insight. 2017;2(19). https://doi.org/10.1172/jci.insight.94416
   PubMed Web of Science ®Google Scholar
• Ponziani FR, Zocco MA, Cerrito L, et al. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications. Expert Rev Gastroenterol Hepatol. 2018 Jul;12(7):641–656. .
   PubMed Web of Science ®Google Scholar
• Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut. 2006 Feb;55(2):205–211. .
   PubMed Web of Science ®Google Scholar
• Zuo T, Kamm MA, Colombel JF, et al. Urbanization and the gut microbiota in health and inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2018;15(7):440–452. .
   PubMed Web of Science ®Google Scholar
• Ni J, Wu GD, Albenberg L, et al. Gut microbiota and IBD: causation or correlation? Nat Rev Gastroenterol Hepatol. 2017 Oct;14(10):573–584. .
   PubMed Web of Science ®Google Scholar
• Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe. 2014 Mar;15(3):382–392. .
   PubMed Web of Science ®Google Scholar
• Schirmer M, Denson L, Vlamakis H, et al. Compositional and temporal changes in the gut microbiome of pediatric ulcerative colitis patients are linked to disease course. Cell Host Microbe. 2018;24(4):600–610.e4. .
   PubMed Web of Science ®Google Scholar
• Tsuzuno T, Takahashi N, Yamada-Hara M, et al. Ingestion of Porphyromonas gingivalis exacerbates colitis via intestinal epithelial barrier disruption in mice. J Periodontal Res. 2021 Apr;56(2):275–288. .
   PubMed Web of Science ®Google Scholar
• Liu L, Liang L, Liang H, et al. Aggravates the progression of colitis by regulating M1 macrophage polarization via AKT2 pathway. Front Immunol. 2019;10:1324.
   PubMed Web of Science ®Google Scholar
• Su W, Chen Y, Cao P, et al. Promotes the development of ulcerative colitis by inducing the autophagic cell death of intestinal epithelial. Front Cell Infect Microbiol. 2020;10:594806.
   PubMed Web of Science ®Google Scholar
• Atarashi K, Suda W, Luo C, et al. Ectopic colonization of oral bacteria in the intestine drives T. Science. 2017;358(6361):359–365. .
   PubMed Web of Science ®Google Scholar
• Kitamoto S, Nagao-Kitamoto H, Jiao Y, et al. The intermucosal connection between the mouth and gut in commensal pathobiont-driven colitis. Cell. 2020;182(2):447–462.e14. .
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P. Inflammatory bowel disease: clinics and pathology. Do inflammatory bowel disease and periodontal disease have similar immunopathogeneses? Acta Odontol Scand. 2001 Aug;59(4):235–243.
   PubMed Web of Science ®Google Scholar
• De Vries SAG, Tan CXW, Bouma G, et al. Salivary function and oral health problems in crohn’s disease patients. Inflamm Bowel Dis. 2018;24(6):1361–1367. .
   PubMed Web of Science ®Google Scholar
• Goldinova A, Tan CX, Bouma G, et al. Oral health and salivary function in ulcerative colitis patients. United European Gastroenterol J. 2020 Nov;8(9):1067–1075. .
   PubMed Web of Science ®Google Scholar
• Wickström C, Svensäter G. Salivary gel-forming mucin MUC5B–a nutrient for dental plaque bacteria. Oral Microbiol Immunol. 2008 Jun;23(3):177–182.
   PubMedGoogle Scholar
• Said HS, Suda W, Nakagome S, et al. Dysbiosis of salivary microbiota in inflammatory bowel disease and its association with oral immunological biomarkers. DNA Res. 2014 Feb;21(1):15–25. .
   PubMed Web of Science ®Google Scholar
• Axelrad JE, Cadwell KH, Colombel JF, et al. The role of gastrointestinal pathogens in inflammatory bowel disease: a systematic review. Therap Adv Gastroenterol. 2021;14:17562848211004493.
   Web of Science ®Google Scholar
• Kelly CJ, Zheng L, Campbell EL, et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host Microbe. 2015 May;17(5):662–671. .
   PubMed Web of Science ®Google Scholar
• Parada Venegas D, De La Fuente MK, Landskron G, et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol. 2019;10:277.
   PubMed Web of Science ®Google Scholar
• Cox MA, Jackson J, Stanton M, et al. Short-chain fatty acids act as antiinflammatory mediators by regulating prostaglandin E(2) and cytokines. World J Gastroenterol. 2009 Nov;15(44):5549–5557. .
   PubMed Web of Science ®Google Scholar
• Bhaskaran N, Quigley C, Paw C, et al. Role of short chain fatty acids in controlling T. Front Microbiol. 2018;9:1995.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar;136(5):E359–86. .
   PubMed Web of Science ®Google Scholar
• Abreu MT, Peek RM. Gastrointestinal malignancy and the microbiome. Gastroenterology. 2014 May;146(6):1534–1546.e3.
   PubMed Web of Science ®Google Scholar
• Arthur JC, Jobin C. The struggle within: microbial influences on colorectal cancer. Inflamm Bowel Dis. 2011 Jan;17(1):396–409.
   PubMed Web of Science ®Google Scholar
• Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host Microbe. 2014 Mar;15(3):317–328.
   PubMed Web of Science ®Google Scholar
• Weisburger JH, Reddy BS, Narisawa T, et al. Germ-free status and colon tumor induction by N-methyl-N’-nitro-N-nitrosoguanidine. Proc Soc Exp Biol Med. 1975 Apr;148(4):1119–1121. .
   PubMed Web of Science ®Google Scholar
• Vannucci L, Stepankova R, Kozakova H, et al. Colorectal carcinogenesis in germ-free and conventionally reared rats: different intestinal environments affect the systemic immunity. Int J Oncol. 2008 Mar;32(3):609–617.
   PubMed Web of Science ®Google Scholar
• Elsalem L, Jum’ah AA, Alfaqih MA, et al. The bacterial microbiota of gastrointestinal cancers: role in cancer pathogenesis and therapeutic perspectives. Clin Exp Gastroenterol. 2020;13:151–185.
   PubMed Web of Science ®Google Scholar
• Rea D, Coppola G, Palma G, et al. Microbiota effects on cancer: from risks to therapies. Oncotarget. 2018 Apr;9(25):17915–17927. .
   PubMedGoogle Scholar
• Wu S, Rhee KJ, Albesiano E, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med. 2009 Sep;15(9):1016–1022. .
   PubMed Web of Science ®Google Scholar
• Arthur JC, Perez-Chanona E, Mühlbauer M, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012 Oct;338(6103):120–123. .
   PubMed Web of Science ®Google Scholar
• Nakatsu G, Li X, Zhou H, et al. Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat Commun. 2015 Oct;6(1):8727. .
   PubMedGoogle Scholar
• Hale VL, Chen J, Johnson S, et al. Shifts in the fecal microbiota associated with adenomatous polyps. Cancer Epidemiol Biomarkers Prev. 2017;26(1):85–94. .
   PubMed Web of Science ®Google Scholar
• Sanapareddy N, Legge RM, Jovov B, et al. Increased rectal microbial richness is associated with the presence of colorectal adenomas in humans. ISME J. 2012 Oct;6(10):1858–1868. .
   PubMed Web of Science ®Google Scholar
• Wu N, Yang X, Zhang R, et al. Dysbiosis signature of fecal microbiota in colorectal cancer patients. Microb Ecol. 2013 Aug;66(2):462–470. .
   PubMed Web of Science ®Google Scholar
• Koliarakis I, Messaritakis I, Nikolouzakis TK, et al. Oral bacteria and intestinal dysbiosis in colorectal cancer. Int J Mol Sci. 2019 Aug;20(17):4146. .
   PubMed Web of Science ®Google Scholar
• Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012 Feb;22(2):292–298. .
   PubMed Web of Science ®Google Scholar
• Candela M, Turroni S, Biagi E, et al. Inflammation and colorectal cancer, when microbiota-host mutualism breaks. World J Gastroenterol. 2014 Jan;20(4):908–922. .
   PubMed Web of Science ®Google Scholar
• Marchesi JR, Dutilh BE, Hall N, et al. Towards the human colorectal cancer microbiome. PLoS One. 2011;6(5):e20447. .
   PubMed Web of Science ®Google Scholar
• Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013 Aug;14(2):207–215. .
   PubMed Web of Science ®Google Scholar
• Mima K, Cao Y, Chan AT, et al. Fusobacterium nucleatum in Colorectal Carcinoma Tissue According to Tumor Location. Clin Transl Gastroenterol. 2016 Nov;7(11):e200. .
   PubMedGoogle Scholar
• Nosho K, Sukawa Y, Adachi Y, et al. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. World J Gastroenterol. 2016 Jan;22(2):557–566. .
   PubMed Web of Science ®Google Scholar
• Mima K, Nishihara R, Qian ZR, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016;65(12):1973–1980. .
   PubMed Web of Science ®Google Scholar
• Serna G, Ruiz-Pace F, Hernando J, et al. Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer. Ann Oncol. 2020;31(10):1366–1375. .
   PubMed Web of Science ®Google Scholar
• Rubinstein MR, Wang X, Liu W, et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013 Aug;14(2):195–206. .
   PubMed Web of Science ®Google Scholar
• Gur C, Ibrahim Y, Isaacson B, et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. 2015 Feb;42(2):344–355. .
   PubMed Web of Science ®Google Scholar
• Yang Y, Weng W, Peng J, et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-κB, and up-regulating expression of MicroRNA-21. Gastroenterology. 2017;152(4):851–866.e24. .
   PubMed Web of Science ®Google Scholar
• Yamaoka Y, Suehiro Y, Hashimoto S, et al. Fusobacterium nucleatum as a prognostic marker of colorectal cancer in a Japanese population. J Gastroenterol. 2018 Apr;53(4):517–524. .
   PubMed Web of Science ®Google Scholar
• Mima K, Sukawa Y, Nishihara R, et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol. 2015 Aug;1(5):653–661. .
   PubMed Web of Science ®Google Scholar
• Ahn J, Sinha R, Pei Z, et al. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst. 2013 Dec;105(24):1907–1911. .
   PubMedGoogle Scholar
• Chen W, Liu F, Ling Z, et al. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS One. 2012;7(6):e39743. .
   PubMed Web of Science ®Google Scholar
• Guven DC, Dizdar O, Alp A, et al. Analysis of fusobacterium nucleatum and streptococcus gallolyticus in saliva of colorectal cancer patients. Biomark Med. 2019;13(9):725–735. .
   PubMed Web of Science ®Google Scholar
• Ryder MI. Porphyromonas gingivalis and Alzheimer disease: recent findings and potential therapies. J Periodontol. 2020;91(Suppl 1):S45–S49.
   PubMedGoogle Scholar
• Pizzo G, Guiglia R, Lo Russo L, et al. Dentistry and internal medicine: from the focal infection theory to the periodontal medicine concept. Eur J Intern Med. 2010 Dec;21(6):496–502. .
   PubMed Web of Science ®Google Scholar
• Figuero E, Sánchez-Beltrán M, Cuesta-Frechoso S, et al. Detection of periodontal bacteria in atheromatous plaque by nested polymerase chain reaction. J Periodontol. 2011 Oct;82(10):1469–1477. .
   PubMed Web of Science ®Google Scholar
• Maekawa T, Krauss JL, Abe T, et al. Porphyromonas gingivalis manipulates complement and TLR signaling to uncouple bacterial clearance from inflammation and promote dysbiosis. Cell Host Microbe. 2014 Jun;15(6):768–778. .
   PubMed Web of Science ®Google Scholar
• Richard ML, Liguori G, Lamas B, et al. Mucosa-associated microbiota dysbiosis in colitis associated cancer. Gut Microbes. 2018;9(2):131–142. .
   PubMed Web of Science ®Google Scholar
• Eslam M, Sanyal AJ, George J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014.e1. .
   PubMed Web of Science ®Google Scholar
• Tilg H, Effenberger M. From NAFLD to MAFLD: when pathophysiology succeeds. Nat Rev Gastroenterol Hepatol. 2020;17(7):387–388.
   PubMed Web of Science ®Google Scholar
• Shiha G, Alswat K, Al Khatry M, et al. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. Lancet Gastroenterol Hepatol. 2021;6(1):57–64. .
   PubMed Web of Science ®Google Scholar
• Sanyal AJ. NASH: a global health problem. Hepatol Res. 2011;41(7):670–674.
   PubMed Web of Science ®Google Scholar
• Liou I, Kowdley KV. Natural history of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006 Mar;40(Suppl 1):S11–6.
   PubMedGoogle Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. .
   PubMed Web of Science ®Google Scholar
• Rinella M, Charlton M. The globalization of nonalcoholic fatty liver disease: prevalence and impact on world health. Hepatology. 2016;64(1):19–22.
   PubMed Web of Science ®Google Scholar
• Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998 Apr;114(4):842–845.
   PubMed Web of Science ®Google Scholar
• Cave M, Deaciuc I, Mendez C, et al. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J Nutr Biochem. 2007 Mar;18(3):184–195. .
   PubMed Web of Science ®Google Scholar
• Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008 Dec;40(12):1461–1465. .
   PubMed Web of Science ®Google Scholar
• Suk KT, Kim DJ. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2019 Mar;13(3):193–204.
   PubMed Web of Science ®Google Scholar
• Leung C, Rivera L, Furness JB, et al. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13(7):412–425. .
   PubMed Web of Science ®Google Scholar
• Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013;57(2):601–609. .
   PubMed Web of Science ®Google Scholar
• Michail S, Lin M, Frey MR, et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol. 2015 Feb;91(2):1–9. .
   PubMed Web of Science ®Google Scholar
• Schwimmer JB, Johnson JS, Angeles JE, et al. Microbiome signatures associated with steatohepatitis and moderate to severe fibrosis in children with nonalcoholic fatty liver disease. Gastroenterology. 2019;157(4):1109–1122. .
   PubMed Web of Science ®Google Scholar
• Caussy C, Tripathi A, Humphrey G, et al. A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. Nat Commun. 2019;10(1):1406. .
   PubMedGoogle Scholar
• Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014 Sep;513(7516):59–64. .
   PubMed Web of Science ®Google Scholar
• Zhou J, Tripathi M, Sinha RA, et al. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. Hepatoma Res. 2021;7:11.
   PubMedGoogle Scholar
• Ponziani FR, Bhoori S, Castelli C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology. 2019;69(1):107–120. .
   PubMed Web of Science ®Google Scholar
• Brignardello J, Morales P, Diaz E, et al. Pilot study: alterations of intestinal microbiota in obese humans are not associated with colonic inflammation or disturbances of barrier function. Aliment Pharmacol Ther. 2010 Dec;32(11–12):1307–1314. .
   PubMed Web of Science ®Google Scholar
• Farhadi A, Gundlapalli S, Shaikh M, et al. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int. 2008 Aug;28(7):1026–1033. .
   PubMed Web of Science ®Google Scholar
• Martin P, DiMartini A, Feng S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American association for the study of liver diseases and the American society of transplantation. Hepatology. 2014 Mar;59(3):1144–1165. .
   PubMed Web of Science ®Google Scholar
• Yoneda M, Naka S, Nakano K, et al. Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease. BMC Gastroenterol. 2012 Feb;12(1):16. .
   PubMedGoogle Scholar
• Nakahara T, Hyogo H, Ono A, et al. Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease. J Gastroenterol. 2018;53(2):269–280. .
   PubMed Web of Science ®Google Scholar
• Takamisawa K, Sugita N, Komatsu S, et al. Association between serum IgG antibody titers against Porphyromonas gingivalis and liver enzyme levels: a cross-sectional study in Sado Island. Heliyon. 2020 Nov;6(11):e05531. .
   PubMed Web of Science ®Google Scholar
• Kudo C, Naruishi K, Maeda H, et al. Assessment of the plasma/serum IgG test to screen for periodontitis. J Dent Res. 2012 Dec;91(12):1190–1195. .
   PubMed Web of Science ®Google Scholar
• Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):656–665.
   PubMed Web of Science ®Google Scholar
• Chakladar J, Wong LM, Kuo SZ, et al. The liver microbiome is implicated in cancer prognosis and modulated by alcohol and hepatitis B. Cancers (Basel). 2020 Jun;12(6):1642. .
   Web of Science ®Google Scholar
• Komiyama EY, Lepesqueur LS, Yassuda CG, et al. Enterococcus species in the oral cavity: prevalence, virulence factors and antimicrobial susceptibility. PLoS One. 2016;11(9):e0163001. .
   PubMed Web of Science ®Google Scholar
• Davis IJ, Richards H, Mullany P. Isolation of silver- and antibiotic-resistant Enterobacter cloacae from teeth. Oral Microbiol Immunol. 2005 Jun;20(3):191–194.
   PubMedGoogle Scholar
• Tsuzukibashi O, Uchibori S, Kobayashi T, et al. Isolation and identification methods of Rothia species in oral cavities. J Microbiol Methods. 2017;134:21–26.
   PubMed Web of Science ®Google Scholar
• Furusho H, Miyauchi M, Hyogo H, et al. Dental infection of Porphyromonas gingivalis exacerbates high fat diet-induced steatohepatitis in mice. J Gastroenterol. 2013 Nov;48(11):1259–1270. .
   PubMed Web of Science ®Google Scholar
• Sasaki N, Katagiri S, Komazaki R, et al. Endotoxemia by Porphyromonas gingivalis Injection Aggravates Non-alcoholic Fatty Liver Disease, Disrupts Glucose/Lipid Metabolism, and Alters Gut Microbiota in Mice. Front Microbiol. 2018;9:2470.
   PubMed Web of Science ®Google Scholar
• Nekvapil F, Pinzaru SC, Barbu-Tudoran L, et al. Color-specific porosity in double pigmented natural 3d-nanoarchitectures of blue crab shell. Sci Rep. 2020;10(1):3019. .
   PubMed Web of Science ®Google Scholar
• Ding LY, Liang LZ, Zhao YX, et al. Porphyromonas gingivalis-derived lipopolysaccharide causes excessive hepatic lipid accumulation via activating NF-κB and JNK signaling pathways. Oral Dis. 2019 Oct;25(7):1789–1797. .
   PubMed Web of Science ®Google Scholar
• Kamata Y, Kessoku T, Shimizu T, et al. Efficacy and safety of PERIOdontal treatment versus usual care for Nonalcoholic liver disease: protocol of the PERION multicenter, two-arm, open-label, randomized trial. Trials. 2020;21(1):291. .
   PubMedGoogle Scholar
• Lankarani KB, Sivandzadeh GR, Hassanpour S. Oral manifestation in inflammatory bowel disease: a review. World J Gastroenterol. 2013 Dec;19(46):8571–8579.
   PubMed Web of Science ®Google Scholar
• Levine JS, Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol. 2011 Apr;7(4):235–241.
   PubMedGoogle Scholar
• Ribaldone DG, Brigo S, Mangia M, et al. Oral manifestations of inflammatory bowel disease and the role of non-invasive surrogate markers of disease activity. Medicines (Basel). 2020 Jun;7(6):33. .
   Google Scholar
• Papageorgiou SN, Hagner M, Nogueira AV, et al. Inflammatory bowel disease and oral health: systematic review and a meta-analysis. J Clin Periodontol. 2017 Apr;44(4):382–393. .
   PubMed Web of Science ®Google Scholar
• Okada M, Kobayashi T, Ito S, et al. Periodontal treatment decreases levels of antibodies to Porphyromonas gingivalis and citrulline in patients with rheumatoid arthritis and periodontitis. J Periodontol. 2013 Dec;84(12):e74–84. .
   PubMed Web of Science ®Google Scholar
• Jakubczyk D, Leszczyńska K, Górska S. The effectiveness of probiotics in the treatment of inflammatory bowel disease (IBD)-A critical review. Nutrients. 2020 Jul;12(7):1973.
   Web of Science ®Google Scholar
• Azad MAK, Sarker M, Wan D. Immunomodulatory effects of probiotics on cytokine profiles. Biomed Res Int. 2018;2018:8063647.
   PubMed Web of Science ®Google Scholar
• Garcia Vilela E, De Lourdes De Abreu Ferrari M, Oswaldo Da Gama Torres H, et al. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn’s disease in remission. Scand J Gastroenterol. 2008;43(7):842–848. .
   PubMed Web of Science ®Google Scholar
• Kato K, Mizuno S, Umesaki Y, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther. 2004 Nov;20(10):1133–1141. .
   PubMed Web of Science ®Google Scholar
• Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic escherichia coli nissle 1917 is as effective as with standard mesalazine. Gut. 2004 Nov;53(11):1617–1623. .
   PubMed Web of Science ®Google Scholar
• Henker J, Müller S, Laass MW, et al. Probiotic escherichia coli nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. Z Gastroenterol. 2008 Sep;46(9):874–875. .
   PubMed Web of Science ®Google Scholar
• Montalban-Arques A, Scharl M. Intestinal microbiota and colorectal carcinoma: implications for pathogenesis, diagnosis, and therapy. EBioMedicine. 2019 Oct;48:648–655.
   PubMed Web of Science ®Google Scholar
• Chitapanarux I, Tungkasamit T, Petsuksiri J, et al. Randomized control trial of benzydamine HCl versus sodium bicarbonate for prophylaxis of concurrent chemoradiation-induced oral mucositis. Support Care Cancer. 2018 Mar;26(3):879–886. .
   PubMed Web of Science ®Google Scholar
• Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015 Nov;350(6264):1084–1089. .
   PubMed Web of Science ®Google Scholar
• Ma YY, Li L, Yu CH, et al. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2013 Oct;19(40):6911–6918. .
   PubMed Web of Science ®Google Scholar
• Kobyliak N, Abenavoli L, Mykhalchyshyn G, et al. A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial. J Gastrointestin Liver Dis. 2018;27(1):41–49. .
   PubMed Web of Science ®Google Scholar
• Shimauchi H, Mayanagi G, Nakaya S, et al. Improvement of periodontal condition by probiotics with Lactobacillus salivarius WB21: a randomized, double-blind, placebo-controlled study. J Clin Periodontol. 2008 Oct;35(10):897–905. .
   PubMed Web of Science ®Google Scholar
• Seminario-Amez M, López-López J, Estrugo-Devesa A, et al. Probiotics and oral health: a systematic review. Med Oral Patol Oral Cir Bucal. 2017 May;22(3):e282–e288. .
   PubMed Web of Science ®Google Scholar
• Xiao L, Zhang Q, Peng Y, et al. The effect of periodontal bacteria infection on incidence and prognosis of cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2020 Apr;99(15):e19698. .
   PubMed Web of Science ®Google Scholar
• Wong SH, Kwong TNY, Chow TC, et al. Quantitation of faecal Fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia. Gut. 2017;66(8):1441–1448. .
   PubMed Web of Science ®Google Scholar
• Janati AI, Karp I, Laprise C, et al. Detection of Fusobaterium nucleatum in feces and colorectal mucosa as a risk factor for colorectal cancer: a systematic review and meta-analysis. Syst Rev. 2020;9(1):276. .
   PubMed Web of Science ®Google Scholar
• Gethings-Behncke C, Coleman HG, Jordao HWT, et al. in the colorectum and its association with cancer risk and survival: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2020;29(3):539–548. .
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhu X, Cao Y, et al. Fecal fusobacterium nucleatum for the diagnosis of colorectal tumor: a systematic review and meta-analysis. Cancer Med. 2019;8(2):480–491. .
   PubMed Web of Science ®Google Scholar
• Rezasoltani S, Sharafkhah M, Asadzadeh Aghdaei H, et al. Applying simple linear combination, multiple logistic and factor analysis methods for candidate fecal bacteria as novel biomarkers for early detection of adenomatous polyps and colon cancer. J Microbiol Methods. 2018;155:82–88.
   PubMed Web of Science ®Google Scholar
• Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016 Mar;63(3):764–775. .
   PubMed Web of Science ®Google Scholar
• Guo Y, Kitamoto S, Kamada N. Microbial adaptation to the healthy and inflamed gut environments. Gut Microbes. 2020;12(1):1857505.
   PubMed Web of Science ®Google Scholar